Unresectable advanced or reccurrent gastrointestinal malignancies
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
Graduate School of Frontier Sciences, University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Must be aged 20 years or older at the time of consent; 2. Solid malignancies diagnosed by histopathological, cytological, or other examinations as the following: i.Colorectal cancer ii.Gastric cancer iii.Esophageal cancer iv.Hepatocellular carcinoma v.Biliary cancer vi.Pancreatic cancer vii.Small intestine cancer viii.Appendix cancer ix.Anal canal cancer x.Neuroendocrine carcinoma of intestinal origin xi.Gastrointestinal stromal tumors xii.Breast cancer xiii.Head and Neck Cancer xiv.Other solid malignancies with specific genetic alterations 3. Must have an unresectable advanced/recurrent malignancy 4. Must have a life expectancy of at least 12 weeks; 5. Must have given written consent; 6. Must have disease progression confirmed on imaging or clinical PD suspected by the study doctor during drug therapy and must have not started subsequent therapy. However, patients with gastric, esophageal or colorectal cancer who has not received any chemotherapy, and patients with breast cancer who has not received any chemotherapy and has specific genetic alterations are eligible. It also targets pancreatic cancer patients under the age of 60 who have not been treated before chemotherapy.
Exclusion criteria
Exclusion criteria: 1. Lymphoid malignancy 2. Have a history of bone marrow or organ transplantation; 3. Are pregnant; or 4. Are judged by the study doctor to be ineligible for the study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of genomic alterations in 74 cancer-associated genes detected by Guardant360 | — |
Countries
Japan
Contacts
Public ContactYoshiaki Nakamura
National Cancer Center Hospital East Department of Gastroenterology and Gastrointestinal Oncology
Outcome results
None listed